Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with ipilimumab versus nivolumab alone in tumor mutational burden-high advanced solid tumors
2016-002898-35Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Nonhematologic neoplasms comparing Nivolumab + ipilimumab with Nivolumab monotherapy (2 arms). Primary endpoint: Objective Response Rate (ORR) in the Tissue Tumor Mutational Burden (tTMB-H) Population. Started Jul 2018; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2016-002898-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002898-35.